The results of phase I clinical trials clearly demonstrated that anti-CD47 blockade enhances antitumor immunity and leads to clinical response in CTCL patients [33,36]. The gene discussed is CD47; the disease is primary cutaneous T-cell non-Hodgkin lymphoma.